Healthy Volunteer Study of Sildenafil Effects Upon Vision

This study has been completed.
Sponsor:
Information provided by:
University of Cambridge
ClinicalTrials.gov Identifier:
NCT00251784
First received: November 9, 2005
Last updated: NA
Last verified: December 2003
History: No changes posted
  Purpose

Patients sometimes report subjective visual effects when taking sildenafil. Our study set out to measure these in a controlled setting. Subjects were asked to detect patterns presented on a monitor screen.


Condition Intervention Phase
Blindness
Drug: Sildenafil
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Educational/Counseling/Training
Official Title: A Double-Blind, Randomised, Placebo Controlled Healthy Volunteer Study to Investigate the Nature and Origin of the Disturbance of Vision Induced by Single Oral Doses of Sildenafil

Resource links provided by NLM:


Further study details as provided by University of Cambridge:

Study Start Date: February 2002
Estimated Study Completion Date: June 2003
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria: male -

Exclusion Criteria:

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00251784

Sponsors and Collaborators
University of Cambridge
Investigators
Principal Investigator: Morris J Brown, MD University of Cambridge
Study Director: John Mollon, FRS University of Cambridge
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00251784     History of Changes
Other Study ID Numbers: LREC 98/297
Study First Received: November 9, 2005
Last Updated: November 9, 2005
Health Authority: United Kingdom: National Health Service

Additional relevant MeSH terms:
Sildenafil
Vasodilator Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents

ClinicalTrials.gov processed this record on September 30, 2014